Fenwick & West LLP represented Audentes Therapeutics Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, in its recently announced $30 million Series A financing. The transaction was led by OrbiMed Advisors with the participation of 5AM Ventures and Versant Ventures. The company plans on utilizing the new funds to advance its two lead programs, AT001 for X-linked Myotubular Myopathy (XLMTM) and AT002 for Pompe disease, and to evaluate additional candidate programs.
In conjunction, Fenwick represented Audentes in a license agreement that gives the company exclusive, global rights to AAV8 and AAV9 in both MTM1 and Pompe disease.
The Fenwick transaction team included partners Matthew Rossiter and Effie Toshav and associates Amit Khanna, Stefano Quintini and Ashley Walter.